CLICK AICI pentru limba ROmana(traducerea „aproximativa” utilizand google translate).
Chelation (pronounced kē’lāt’shun) therapy is generally regarded by the medical community to be the use of chelating agents to remove toxic heavy metals from the body.
“Chelation” is derived from the Greek “chela” meaning claw.
Mercury, nickel, lead, and aluminum are all considered heavy (toxic) metals. They can enter our bodies from many sources including automotive exhaust, cosmetics, paint, evaporated milk, infant formulas, baby powder, bleached white flour, pharmaceutical drugs, antacids, tooth paste, and aspirin. Heavy metals can block the natural detoxification processes. This can lead to fatigue, nutritional deficiencies, and numerous other health-related issues. Chelation therapy safely and effectively removes heavy metals from the body’s cells and tissues. The word “chelation” comes from the Greek work chele, which means claw. Chelation therapy can be administered orally (pills) or by injection. The therapy can be helpful in improving blood circulation and can be part of the Personalized Treatment Plan for patients with various conditions. Chelation therapy (oral or intravenous) will clear the arteries, the blood, and will remove toxic metals like mercury, cadmium and lead.
Modern chelation therapy with EDTA is a simple, safe, and effective procedure. During the therapy the patient comfortably relaxes in the doctor’s office while fluid is administered into the vein. The fluid contains chelating substances which grab harmful chemicals in a claw-like manner and eventually carry the chemicals out of the body through the urine.
Chelation therapy removes chemicals that form plaque, the substance responsible for hardening and clogging the arteries which interferes with the normal cellular process. In the United States, hardening of the arteries has been found to be an underlying condition in most deaths caused by disease. Osteoporosis and arthritic degenerative joint disease can also be controlled or reversed. In this way, more invasive surgeries like bypass and limb amputation due to poor circulation can be avoided.
These chelating substances are virtually non-toxic when used as directed. Toxic heavy metals include but are not limited to Arsenic, Cadmium, Lead, and Mercury. The chelating agent EDTA (ethylene diamine tetra acetic acid) was first used clinically in the 1940’s. EDTA comes in two injectable forms, both of which remove lead and have been approved by the U.S. Food and Drug Administration (FDA): Calcium disodium EDTA treats lead toxicity and Disodium EDTA treats elevated blood concentrations of calcium. These and other medical chelating agents such as DMPS (2, 3 dimercapto-propane sulfonate), DMSA (dimercaptosuccinic acid) penicillamine (3-mercapto-D-valine), and DFO (desferrioxamine) have distinctive effectiveness for removing different metals. Magnesium disodium EDTA has been popularly used to intravenously treat cardiovascular, autoimmune and other degenerative diseases.
Experienced physicians in chelating can best evaluate toxic metal burdens in order to select targeted chelating substances to most appropriately treat a patient’s specific needs.
The chart below depicts how different metals underlie an array of problems.
The American Board of Chelation Therapy which certifies physicians with toxic metal expertise, inclusive of chelation therapy, has recently changed its name to the American Board of Clinical Metal Toxicology. This was changed to in part to better reflect the need to address the bigger picture of heavy metal toxicity. We need to be environmentally proactive, to clean up contaminated areas, to control industrial and agricultural wastes, to remove toxic metals from vaccines and dentistry, and to educate the public in regard to the presence of toxic metals in products we use and consume. Dr. Dayton, who was among the first to be Board Certified in 2003, has administered these tests to many candidates.
Intravenous Chelation Therapy using the substance EDTA involves cleansing the body of harmful toxic metals which are implicated in many diseases. With chelation therapy, circulatory conditions associated with hardening of the arteries leading to stroke, hypertension, angina, heart attack, memory loss, poor vision and impotence may be improved. In this way, the more invasive bypass surgery and limb amputation due to poor circulation can be avoided.
Chelation therapy stimulates the body to restore strength to the bones and removes chemicals that cause joint stiffening and pain. Chelation therapy removes toxic chemicals which interfere with normal biochemical functions. Cosmetically, skin wrinkles are improved. Chelation therapy combats various degenerative processes. Chelation has been shown to be effective in the prevention of malignancy.
Chelation therapy counteracts destructive chemicals which are constantly formed in the body. These chemicals cause degeneration associated with aging. In laboratory tests, the life expectancy of living cells exposed to intravenous chelation substances was extended many-fold. Improvement in human longevity with intravenous chelation therapy appears promising.
Despite five decades of use in treatment of cardiovascular disease intravenous EDTA remains controversial for treatment of cardiovascular conditions. Studies favoring the use of intravenous EDTA in treatment of cardiovascular disease and other degenerative diseases have been published in medical literature since the 1950’s. N.E. Clarke, published in the American Journal of Science in 1956 that 19 out of 20 patients with angina received unusual relief with normalization of electrocardiograms for some. Other benefits reported during this period, as they are still being reported today, include improved memory; better sight; hearing and smell; and an increase in energy. Heavy metal toxicity interferes with normal physiologic function and repair leading to numerous symptoms and contributing too many diseases. Multiple conditions in the same individual may be alleviated simultaneously through the reduction of heavy metal toxicity.
Chelation therapy with EDTA to remove heavy metals from the blood in order to treat coronary disease has been around– and provoked criticism– since the 1950s. Despite a lack of apparent evidence and the skepticism of the medical community, passionate supporters have kept the therapy alive in alternative medicine circles. Apparently, they never considered a study published by W.Blumer and E.M.Cranton in the Journal of Advancement of Medicine which followed 231 subjects over the course of 18 years, ultimately reporting a 90% reduction in cancer mortality in patients having had received 10 or more Calcium EDTA infusions compared to those who did not.
More scientific studies about calcium and cancer in the scientific studies database click here
In a recent article entitled NIH Trial Gives Surprising Boost To Chelation Therapy, by medical journalist, Larry Husten, that appeared in the November 4, 2012 issue of Forbes Magazine, a large NIH-sponsored trial surprised the mainstream medical community when it presented substantial evidence in support of chelation therapy for patients with coronary disease. Known as TACT (Trial to Assess Chelation Therapy), the highly controversial trial was presented at the AHA by Gervasio Lamas. The trial was sponsored by two NIH institutes, the National Center for Complementary and Alternative Medicine and the National Heart Lung and Blood Institute. TACT was funded by the NIH more than a decade ago as part of a much-publicized initiative to study the claims of alternative medicine. In 2008 enrollment in TACT was temporarily suspended in response to claims that the trial was unethical. The trial was additionally hampered by slow enrollment. However, the trial recommended the use of EDTA preventively as well as therapeutically.
Intravenous DMPS chelation therapy, as performed in this office, typically involves DMPS followed by glutathione, and then followed by vitamin C all administered intravenously, the total procedure taking approximately 1-2 hours. Glutathione and vitamin C improve effectiveness and reduce chances of adverse reactions. Vitamin C helps to additionally remove toxic metals. The frequency of intravenous administrations varies with individual patient circumstances, once weekly being average. DMPS is often used to target mercury toxicity. EDTA may be used to target lead. Both DMPS and EDTA remove various toxic metals but to different degrees.
IV EDTA Chelation Therapy
“Health is too dear to be left to chance alone.”
The Case for Intravenous EDTA Chelation Therapy has been acclaimed as an easy read educational book for both patients and doctors on the benefits of chelation therapy. The book as of October, 2012 continues to remain up to date in significant information although it was last published in1999.The first edition of the book was written in a day when the nonemergency coronary bypass, stent, and angioplasty procedures were touted to prevent heart attack and cardiac death. Doctors often sold these lucrative therapies to their patients by telling their patients they are “walking time bombs.” More recently, these invasive therapies have been statistically proven to not prevent heart attacks or early coronary death when performed in the non-acute setting. Unfortunately, secondary infirmities and occasionally death have been statistically proven to occur with such invasive therapies. Although, intravenous EDTA chelation has been shown to be a safe, effective and less expensive medical alternative, it still remains controversial within the medical community regarding if it is acceptably proven or not.
A large sophisticated controlled study involving many patients performed over a long period of time is needed to address the controversy regarding the effective use of chelation therapy in coronary heart disease. The study named, Trial to Assess Chelation Therapy (TACT), funded for $30,000,000 by the NIH has been performed under the guidance of chief investigator Gervasio Lamas M.D. The Case for EDTA Chelation Therapy was used as a reference in developing the study.
The results of the Trial to Assess Chelation Therapy (TACT) NIH funded study was announced at the American Heart Association meeting on Nov. 4, 2012. The study involved over 1700 patients who have had at least one previous myocardial infarction over the course of several years. For patients who received intravenous EDTA chelation therapy the composite statistics for death, MI, stroke, coronary revascularization, and hospitalization for angina were significantly lower than for those in a matched group who did not receive the therapy. Death from heart attacks were reduced by 18% and for diabetics over 39%.
Although statistically demonstrated as beneficial for coronary artery disease, chelation therapy remains controversial as is the TACT study which supports it.
The author of The Case for EDTA Chelation Therapy, Martin Dayton D.O., has been administering intravenous EDTA chelation since 1999 and was among the first to be board certified in 1983.
Please enjoy the complimentary bookdown load.
You can download the book for FREE by clicking here.
Intravenous DMPS Provocative challenge test
After the intravenous procedure is completed urine is collected in a container over the range of 6 to 20 hours depending upon individual patient need. The toxic burden of toxic metals, including mercury, is indirectly measured in the urine The total volume of fluid is measured by recording the number on the gradation scale of the urine container corresponding to fluid level within. Urine from the container is placed into a small tube which is sealed and mailed to the laboratory along with a record of the total urine volume. The laboratory results are interpreted by the doctor once they arrive from the laboratory.
The combination of the DMPS infusion and the analysis of the toxic metal content in the urine is called the “provocative challenge test.” This test measures the excretion of metals in the urine provoked by the DMPS infusion. This test is performed periodically to gain clinically strategic information about the body burden of toxic metals, quantitatively and qualitatively.
Information taken from: http://daytonmedical.com
Things that you can do (take at home ) to help with Chelation include zeolites, algae(Spirulina, Clorella ), Gluthatione, Green tea, Vitamin C, clorophyll (from green foods such as algae, wheatgrass & barleygrass, etc), Garlic & onions ,etc.
Best of health!
SHARE, LIKE, COMMENT – buttons below!